|Articles|January 1, 2005

Trial to study potential MMD treatment

Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME

Video

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

Video

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

Trial to study potential MMD treatment

Related Content

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

Emerging dry eye therapies and co-managing MGD: Ping Moore, OD

Why aren’t there enough ophthalmologists?

Personalizing dry eye treatment by addressing disease at its source

Root cause–based dry eye classification and the shift toward precision medicine

Latest CME

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Trending on Eye Care Network - Ophthalmology Times

Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP

Retina Society 2026: Non-invasive electrical stimulation therapy for intermediate dry AMD: improved retinal health and visual acuity

Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial

Retina Society 2026: LUGANO secondary data show reduced treatment burden with vorolanib insert despite missed primary end point

Beyond the phenotype: Aqueous humor sampling moves retinoblastoma toward personalized therapy